167 related articles for article (PubMed ID: 22126913)
1. Abnormal metabolic brain networks in a nonhuman primate model of parkinsonism.
Ma Y; Peng S; Spetsieris PG; Sossi V; Eidelberg D; Doudet DJ
J Cereb Blood Flow Metab; 2012 Apr; 32(4):633-42. PubMed ID: 22126913
[TBL] [Abstract][Full Text] [Related]
2. Modulation of Abnormal Metabolic Brain Networks by Experimental Therapies in a Nonhuman Primate Model of Parkinson Disease: An Application to Human Retinal Pigment Epithelial Cell Implantation.
Peng S; Ma Y; Flores J; Cornfeldt M; Mitrovic B; Eidelberg D; Doudet DJ
J Nucl Med; 2016 Oct; 57(10):1591-1598. PubMed ID: 27056614
[TBL] [Abstract][Full Text] [Related]
3. Cerebral metabolic pattern associated with progressive parkinsonism in non-human primates reveals early cortical hypometabolism.
Molinet-Dronda F; Blesa J; Del Rey NL; Juri C; Collantes M; Pineda-Pardo JA; Trigo-Damas I; Iglesias E; Hernández LF; Rodríguez-Rojas R; Gago B; Ecay M; Prieto E; García-Cabezas MÁ; Cavada C; Rodríguez-Oroz MC; Peñuelas I; Obeso JA
Neurobiol Dis; 2022 Jun; 167():105669. PubMed ID: 35219857
[TBL] [Abstract][Full Text] [Related]
4. Overlesioned hemiparkinsonian non human primate model: correlation between clinical, neurochemical and histochemical changes.
Oiwa Y; Eberling JL; Nagy D; Pivirotto P; Emborg ME; Bankiewicz KS
Front Biosci; 2003 Sep; 8():a155-66. PubMed ID: 12957824
[TBL] [Abstract][Full Text] [Related]
5. L-DOPA regulates α-synuclein accumulation in experimental parkinsonism.
Deffains M; Canron MH; Teil M; Li Q; Dehay B; Bezard E; Fernagut PO
Neuropathol Appl Neurobiol; 2021 Jun; 47(4):532-543. PubMed ID: 33275784
[TBL] [Abstract][Full Text] [Related]
6. Aged monkeys as a partial model for Parkinson's disease.
Hurley PJ; Elsworth JD; Whittaker MC; Roth RH; Redmond DE
Pharmacol Biochem Behav; 2011 Sep; 99(3):324-32. PubMed ID: 21620883
[TBL] [Abstract][Full Text] [Related]
7. A non-human primate model for stable chronic Parkinson's disease induced by MPTP administration based on individual behavioral quantification.
Seo J; Lee Y; Kim BS; Park J; Yang S; Yoon HJ; Yoo J; Park HS; Hong JJ; Koo BS; Baek SH; Jeon CY; Huh JW; Kim YH; Park SJ; Won J; Ahn YJ; Kim K; Jeong KJ; Kang P; Lee DS; Lim SM; Jin YB; Lee SR
J Neurosci Methods; 2019 Jan; 311():277-287. PubMed ID: 30391524
[TBL] [Abstract][Full Text] [Related]
8. In vivo PET studies of the dopamine D2 receptors in rhesus monkeys with long-term MPTP-induced parkinsonism.
Doudet DJ; Holden JE; Jivan S; McGeer E; Wyatt RJ
Synapse; 2000 Nov; 38(2):105-13. PubMed ID: 11018784
[TBL] [Abstract][Full Text] [Related]
9. The utility of susceptibility-weighted imaging for differentiating Parkinsonism-predominant multiple system atrophy from Parkinson's disease: correlation with 18F-flurodeoxyglucose positron-emission tomography.
Yoon RG; Kim SJ; Kim HS; Choi CG; Kim JS; Oh J; Chung SJ; Lee CS
Neurosci Lett; 2015 Jan; 584():296-301. PubMed ID: 25450142
[TBL] [Abstract][Full Text] [Related]
10. Mapping dopamine function in primates using pharmacologic magnetic resonance imaging.
Jenkins BG; Sanchez-Pernaute R; Brownell AL; Chen YC; Isacson O
J Neurosci; 2004 Oct; 24(43):9553-60. PubMed ID: 15509742
[TBL] [Abstract][Full Text] [Related]
11. Different metabolic patterns analysis of Parkinsonism on the 18F-FDG PET.
Juh R; Kim J; Moon D; Choe B; Suh T
Eur J Radiol; 2004 Sep; 51(3):223-33. PubMed ID: 15294329
[TBL] [Abstract][Full Text] [Related]
12. D(1) dopamine receptor agonists are more effective in alleviating advanced than mild parkinsonism in 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-treated monkeys.
Goulet M; Madras BK
J Pharmacol Exp Ther; 2000 Feb; 292(2):714-24. PubMed ID: 10640310
[TBL] [Abstract][Full Text] [Related]
13. Abnormal metabolic networks in atypical parkinsonism.
Eckert T; Tang C; Ma Y; Brown N; Lin T; Frucht S; Feigin A; Eidelberg D
Mov Disord; 2008 Apr; 23(5):727-33. PubMed ID: 18186116
[TBL] [Abstract][Full Text] [Related]
14. Deep brain stimulation reduces neuronal entropy in the MPTP-primate model of Parkinson's disease.
Dorval AD; Russo GS; Hashimoto T; Xu W; Grill WM; Vitek JL
J Neurophysiol; 2008 Nov; 100(5):2807-18. PubMed ID: 18784271
[TBL] [Abstract][Full Text] [Related]
15. Effects of high-frequency stimulation of the internal pallidal segment on neuronal activity in the thalamus in parkinsonian monkeys.
Kammermeier S; Pittard D; Hamada I; Wichmann T
J Neurophysiol; 2016 Dec; 116(6):2869-2881. PubMed ID: 27683881
[TBL] [Abstract][Full Text] [Related]
16. Dystonia is predictive of subsequent altered dopaminergic responsiveness in a chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine+3-nitropropionic acid model of striatonigral degeneration in monkeys.
Ghorayeb I; Fernagut PO; Stefanova N; Wenning GK; Bioulac B; Tison F
Neurosci Lett; 2002 Dec; 335(1):34-8. PubMed ID: 12457736
[TBL] [Abstract][Full Text] [Related]
17. A disease-specific metabolic brain network associated with corticobasal degeneration.
Niethammer M; Tang CC; Feigin A; Allen PJ; Heinen L; Hellwig S; Amtage F; Hanspal E; Vonsattel JP; Poston KL; Meyer PT; Leenders KL; Eidelberg D
Brain; 2014 Nov; 137(Pt 11):3036-46. PubMed ID: 25208922
[TBL] [Abstract][Full Text] [Related]
18. Diffusion tensor imaging marks dopaminergic and serotonergic lesions in the Parkinsonian monkey.
Météreau E; Beaudoin-Gobert M; Duperrier S; Thobois S; Tremblay L; Sgambato-Faure V
Mov Disord; 2018 Feb; 33(2):298-309. PubMed ID: 29076602
[TBL] [Abstract][Full Text] [Related]
19. Mouse model of Parkinsonism: a comparison between subacute MPTP and chronic MPTP/probenecid treatment.
Petroske E; Meredith GE; Callen S; Totterdell S; Lau YS
Neuroscience; 2001; 106(3):589-601. PubMed ID: 11591459
[TBL] [Abstract][Full Text] [Related]
20. Differences in alpha7 nicotinic acetylcholine receptor binding in motor symptomatic and asymptomatic MPTP-treated monkeys.
Kulak JM; Schneider JS
Brain Res; 2004 Mar; 999(2):193-202. PubMed ID: 14759498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
